Weitai Medical-B (02235): AIDex G9, a continuous glucose monitoring system, was registered and approved by the State Drug Administration

Zhitong Finance App News, Weitai Medical-B (02235) issued an announcement. Recently, the company's next-generation split continuous glucose monitoring system AiDex G9 was approved for marketing by the State Drug Administration. Compared to first-generation split products, AiDex G9 has achieved innovative changes in technical architecture, and has been comprehensively upgraded in size, lightness and wearing comfort, so that diabetics can enjoy a lighter and more comfortable experience in blood sugar management.

China is one of the largest diabetes markets in the world. According to the International Diabetes Federation (IDF) “2025 Global Diabetes Map” data, in 2024, there were about 148 million diabetic adults aged 20 to 79 in China, ranking first in the world. At the same time, the number of people with pre-diabetes in China reached 274 million, making up a huge group of people potentially at high risk of diabetes. The approval of this product will further enrich the Group's product pipeline, achieve wider user coverage, help the Group seize development opportunities in the Chinese market, and consolidate and enhance the Group's market position and competitive advantage in the field of continuous glucose monitoring.

In the future, the company will continue to focus on the global development of diabetes monitoring, treatment and management methods, and continue to promote technological and product innovation in related fields.